A Study To Assess The Effect Of PF-03526299 On Lung Function Following An Allergen Challenge In Asthmatic Subjects

A Randomized, Double-Blind, Double-Dummy, Placebo Controlled, 3-Way Crossover Study To Determine The Effects Of Inhaled Doses Of PF-03526299 On Allergen-Induced Airway Responses In Mild Asthmatic Subjects.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00877539

Enrollment

Registered

2009-04-07

Start date

2009-06-30

Completion date

2010-07-31

Last updated

2010-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

Asthma Allergen Challenge

Brief summary

PF-03526299, a novel anti-inflammatory agent should attenuate the effect of a bronchial allergen challenge on lung function and hence provide proof of mechanism for this agent.

Interventions

DRUGPF-03526299

Inhaled, two doses 4 hours apart

DRUGPlacebo

Inhaled, two doses 4 hours apart

DRUGFluticasone propionate

Inhaled

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Males and females 18-60 years * Mild asthma * Atopic to allergens

Exclusion criteria

* Unstable asthma * Smokers or recent ex-smokers * Recent allergen challenge

Design outcomes

Primary

Measure	Time frame
Spirometry pre- and post- bronchial allergen challenge	2 months

Secondary

Measure	Time frame
Laboratory safety tests	2 months
12-lead ECGs	2 months
Adverse Event reporting	2 months
Blood samples for pharmacokinetic measurement	2 months
Sputum for pharmacodynamic measurement	2 months

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026